Market Overview

Piper Jaffray Not Convinced MannKind's Afreeza Will Be Commercial Success

Related MNKD
38 Biggest Movers From Yesterday
Applied Optoelectronics, Helios And Matheson Among The Top Stocks With Short Sellers

On Wednesday, Piper Jaffray raised the price target for MannKind (NASDAQ: MNKD) from $1.50 to $2 and reiterated an Underweight rating following the FDA Advisory Committee recommended the approval of Afrezza.

Analyst Joshua Schimmer believes the FDA will need added time to negotiate a “complex label,” which may delay the drug beyond the April 15 PDUFA date or force MannKind to provide more information on the drug.

Afrezza is not a slam dunk to be a commercial success and the drug will not be on the market until 2016, Schimmer said.

The possibility of lung cancer as a side effect may discourage patients from using the drugs and new diabetics may opt for the traditional injectable insulin rather than unproven inhaled insulin.

Other firms have adjusted their price targets for MannKind including:

  • Griffin Securities -- Raises PT from $12.50 to $13, maintained Buy rating.
  • Cowen & Co. -- Lowers PT from $5.50 to $5, maintained Mark Perform rating.
  • MLV & Co. -- Raises PT from $9 to $11, maintained Buy rating.
  • J.P. Morgan -- Maintained $6 PT, maintained Neutral rating.

Shares of MannKind opened at $7.74 on Wednesday after closing at $3.80 on Tuesday. The stock has traded in a range between $8.08 and $6.83.

Latest Ratings for MNKD

Oct 2017H.C. WainwrightInitiates Coverage OnBuy
Aug 2017Maxim GroupInitiates Coverage OnBuy
Nov 2015Griffin SecuritiesDowngradesBuyNeutral

View More Analyst Ratings for MNKD
View the Latest Analyst Ratings

Posted-In: Joshua Schimmer Piper JaffrayAnalyst Color Price Target Reiteration Analyst Ratings


Related Articles (MNKD)

View Comments and Join the Discussion!

Partner Center